STE · 10-Q · 2026Q2 · Full report

Operating Expense Trends

STERIS plc · 2026-08-07 · Importance 42 · Surprise 14

Total operating expenses increased 4.3% to $398.3 million in the first quarter of fiscal 2027 from $382.0 million. SG&A increased 4.5% to $369.7 million, primarily because of higher compensation and benefits and marketing and sales costs, partly offset by favorable foreign currency and lower bad-debt expense. Research and development expense increased 8.5% to $28.6 million from $26.4 million. R&D investment focused on sterile-processing technologies, procedural products and accessories, and gastrointestinal endoscopy devices and support accessories.

Key facts

• Selling, general, and administrative (SG&A) expenses for the three months ended June 30, 2026: $369.7 million, compared to $353.8 million for the three months ended June 30, 2025 (4.5% increase). source
• Total operating expenses for the three months ended June 30, 2026: $398.3 million, compared to $382.0 million for the three months ended June 30, 2025 (4.3% increase). source
• Research and development expenses for the three months ended June 30, 2026: $28.6 million, compared to $26.4 million for the three months ended June 30, 2025 (8.5% increase). source